Article

STAAR Surgical consolidates lens operations in Monrovia, CA

Implantable contact lens and preloaded IOL manufacturing will move to California in a consolidation project now under way at STAAR Surgical.

Monrovia, CA-An 8-year lease on a 26,000-square-foot building next to its current facility in Monrovia, CA, will allow STAAR Surgical Co. to consolidate its finished goods inventory and shipping departments and prepare for future growth, according to the company.

The new facility, which STAAR expects to be under lease by November, will be connected to the company’s current 44,000-square-foot facility via two direct hallways and will add 57 parking spots.

“With the new building, we have gained flexibility in our working processes that will help drive enhanced efficiencies and productivity,” said Barry G. Caldwell, president and chief executive officer of STAAR. “For example, the sales, marketing, research and development, and regulatory functions will be positioned in the same work area to enhance communications and working relations.”

The company began the consolidation project more than 2 years ago and expects to complete it by the end of 2013. The manufacturing of its implantable contact lens ([ICL] Visian Implantable Collamer Lens) and preloaded IOLs will move to Monrovia from Nidau, Switzerland, and Ichikawa City, Japan, respectively, and the process associated with the raw material of the collagen copolymer used in the ICL will move from Aliso Viejo, CA.

The company expects the changes to add to the expanding gross margin percentage as well as reduce the company’s tax rate from 50% in 2011 to 10% in 2014. The cost savings over 7 years is expected to exceed $100 million, according to STAAR.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.